Previous close | 23.73 |
Open | 23.56 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 23.26 - 23.70 |
52-week range | 22.49 - 30.42 |
Volume | |
Avg. volume | 4,227 |
Market cap | 14.79B |
Beta (5Y monthly) | 0.52 |
PE ratio (TTM) | 9.68 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.26 (5.34%) |
Ex-dividend date | 29 Apr 2024 |
1y target est | N/A |
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.